Table 2.

Multivariable models of blood eosinophil count ≥ 300 cells/μL and exacerbation risk in COPDGene.

	COPDGene: Year Prior to Visit 2 (Cross sectional)				COPDGene: Longitudinal Follow Up
	Exacerbation Frequency* (n=1553)		Frequent Exacerbations† (n=1281)		Exacerbation Rate* (n=1113)
Factors	IRR* (95% CI)	p value	OR† (95% CI)	p value	IRR* (95% CI)	p value
Age	0.98 (0.97–1.00)	0.007	0.96 (0.94–0.99)	0.003	0.99(0.97–1.01)	0.48
Female	1.43 (1.20–1.71)	<0.001	1.83(1.30–2.58)	<0.001	0.87(0.65–1.15)	0.31
Non White Race	0.73 (0.57–0.92)	0.008	0.63(0.40–0.99)	0.05	1.73 (1.19–2.55)	0.005
SGRQ total score‡	1.02 (1.02–1.03)	<0.001	1.04(1.03–1.05)	<0.001	1.02(1.01–1.03)	<0.001
post-bronchodilator FEV1 % predicted §	0.98 (0.98–0.99)	<0.001	0.97(0.96–0.98)	<0.001	0.99(0.98–1.00)	0.003
GERD	1.33 (1.11–1.59)	0.002	1.35(0.95–1.91)	0.09	1.08(0.81–1.45)	0.57
Current smoking	0.71(0.57–0.89)	0.002	0.56(0.37–0.84)	0.006	0.63(0.45–0.90)	0.01
Previous Exacerbations	NA	NA	NA	NA	2.51(1.87–3.37)	<0.001
WBC	1.00 (0.96–1.04)	0.97	1.02(0.94–1.10)	0.66	1.03(0.96–1.10)	0.44
Eosinophil ≥300	1.32 (1.08–1.61)	0.006	1.58(1.07–2.30)	0.019	1.33(0.92–1.95)	0.13

^*Risk estimate from negative binomial regression.

^†Odds ratio from logistic regression comparing subjects with 2 or more exacerbations per year to subjects with less than 1 exacerbation per year.

^‡per 1 point increase in score,

^§per percentage point increase in FEV₁